Approval for Weekly Byetta Sought by Amylin, Lilly

摘要

Amylin Pharmaceuticals has submitted an NDA for a weekly version of its diabetes drug Byetta.rnAmylin, Eli Lilly and Alkermes are working together to develop exenatide once weekly, a subcutaneous injection for the treatment of Type 2 diabetes, according to an Amylin spokeswoman. The weekly form of Byetta (exenatide) was more effective than the approved version of Byetta, which is injected twice a day, Amlyin says in a statement last week.